Literature DB >> 23673545

Current concepts in MRI of focal and diffuse malignancy of bone marrow.

Benjamin Matthew Howe1, Geoffrey B Johnson, Doris E Wenger.   

Abstract

Bone marrow is a ubiquitous component of musculoskeletal imaging studies. The ability to identify and characterize pathology accurately in the bone marrow can be challenging given the broad spectrum of imaging features of normal bone marrow. Knowledge regarding the ability to differentiate normal from abnormal marrow has been enhanced with MR imaging with numerous techniques available to aid in distinguishing benign from malignant lesions in the bone marrow. T1-weighted fast spin echo (FSE) and fluid-sensitive sequences, fat-saturated T2-weighted FSE, and short tau inversion recovery provide valuable tools for the evaluation of a focal bone marrow lesion. Gadolinium enhancement, chemical shift, diffusion-weighted, and MR spectroscopy imaging are additional tools available for focal bone marrow lesion evaluation. Whole-body MRI and fluorodeoxyglucose positron emission tomography-computed tomography have evolved to be useful studies for staging and monitoring of therapeutic response in whole-body imaging. The relative advantages and disadvantages of the whole-body techniques are reviewed for metastases, myeloma, and lymphoma. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23673545     DOI: 10.1055/s-0033-1343069

Source DB:  PubMed          Journal:  Semin Musculoskelet Radiol        ISSN: 1089-7860            Impact factor:   1.777


  4 in total

Review 1.  Bone tumor imaging, then and now: review article.

Authors:  Douglas N Mintz; Sinchun Hwang
Journal:  HSS J       Date:  2014-07-16

2.  Advanced MR imaging of bone marrow: quantification of signal alterations on T1-weighted Dixon and T2-weighted Dixon sequences in red marrow, yellow marrow, and pathologic marrow lesions.

Authors:  Chayanit Sasiponganan; Kevin Yan; Parham Pezeshk; Yin Xi; Avneesh Chhabra
Journal:  Skeletal Radiol       Date:  2019-10-12       Impact factor: 2.199

Review 3.  GD2-targeted immunotherapy and radioimmunotherapy.

Authors:  Konstantin Dobrenkov; Nai-Kong V Cheung
Journal:  Semin Oncol       Date:  2014-07-21       Impact factor: 4.929

4.  Proposal for a Quantitative 18F-FDG PET/CT Metabolic Parameter to Assess the Intensity of Bone Involvement in Multiple Myeloma.

Authors:  Maria E S Takahashi; Camila Mosci; Edna M Souza; Sérgio Q Brunetto; Elba Etchebehere; Allan O Santos; Mariana R Camacho; Eliana Miranda; Mariana C L Lima; Barbara J Amorim; Carmino de Souza; Fernando V Pericole; Irene Lorand-Metze; Celso D Ramos
Journal:  Sci Rep       Date:  2019-11-11       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.